Nevimune belongs to a group of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs) Nevimune is a prescription medicine recognized by the U.S FDA for the prevention of HIV infection in adults and children. Nevimune is always used in combination with other HIV medicines. Nevimune comes in three different forms: immediate-release tablets and oral suspension (a liquid), and extended-release tablets
Nevimune is indicated in co administration with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Mechanism of Nevimune
Nevimune isa type of non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1.
Nevimune interpolated directly to reverse transcriptase (RT) and prevents the RNA- dependent and DNA-dependent DNA polymerase action by making a division of the enzyme's catalytic site.
The activities of Nevimune have not refined with template or nucleoside triphosphates.
HIV-2 RT and eukaryotic DNA polymerases such as human DNA polymerases α, ß, γ, or δ are not prohibit by nevirapine.
Bioavailability in human is 93±9% and 91 ± 8% for oral solution and in rate is 89.7%. High plasma concentration is 2 ± 0.4 mcg/ml attained by 4 hours.
human Albumin of Plasma protein binding is 60%
Nevimune extensively bio transformed via cytochrome P450 and metabolized to several hydroxylated metabolites
Total radioactive in urine is 80% was made up of gluvuronide conjugation. The drug eliminated via urine 81.8 ± 11.1% and feces in 10.1 ± 1.5% Half life is 45 hours
For adult recommended dose
In Co administration with other antiretroviral agents the recommended dose for Nevimune is one tablet of 200 mg daily for the first 14 days, followed by one 200 mg tablet twice daily,
The 14-day lead-in period with Nevimune 200 mg daily dosing should be strictly followed as the lead-in period has been observed to decrease the incidence of rash.
If rash continueapart from the 14-day lead-in period, do not dose expand to 200 mg twice daily. The 200 mg once-daily dosing drugs should not be continued above 28 days, at which point, an alternative drugs should be desired. For combination administered antiretroviral therapy, Thenormal dosage and monitoring should be followed.
The recommended oral dose for pediatric patients 15 days and older :150 mg/m 2 given once daily for period of 14 days followed by 150 mg/m 2 administered twice daily thereafter. The entiredose for daily should not exceed 400 mg for any patient.
Common side effects may include
Skin rash; or changes in the s location of body fat (specifically in your arms, legs, face, neck, breasts, and waist).
Serious side effects
Fever, night sweats, Swollen glands, Mouth sores, diarrhea, stomach pain, weight loss; Chest pain (specifically when you breathe), Dry cough, wheezing, feeling short of breath; cold sores, sores on your genital or anal area; Rapid heart rate, Feeling anxious or irritable, Weakness or prickly feeling, Problems with balance or eye movement; Trouble speaking or swallowing, Severe lower back pain, Loss of bladder or bowel control; or Swelling in your neck or throat (enlarged thyroid), Menstrual changes, Impotence, Loss of interest in sex.
Patients are contraindicated with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment For indicated as part of occupational and non-occupational post-exposure prophylaxis (PEP) drugs.
Serious and life-threatening skin reactions, involves fatal cases, have been reported in patients taking Nevimune .
Hepatotoxicity and hepatic impairment
Serious life-threatening in patient, and in some cases fatal hepatotoxicity, containing fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, have been reported in patients treated with Nevimune .
Redistribution/aggregation of body fat involves central obesity, buffalo hump (dorsocervical fat enlargement), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy
Consolidation of Nevimunewith efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy.
Immune reconstitution syndrome has been resulted in patients reacted with combination antiretroviral therapy, including Nevimune . During the initial phase of combination antiretroviral treatment, patients whose immune system behave may grow an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, tuberculosis, cytomegalovirus or Pneumocystis jiroveci pneumonia), which may necessitate further evaluation and treatment.